Race Initiates University of Newcastle Collaboration to Develop a Genomics-based Companion Diagnostic for Zantrene
Race Initiates University of Newcastle Collaboration to Develop a Genomics-based Companion Diagnostic for Zantrene
3 November 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle to develop a companion diagnostic to support...
Race Submits Human Ethics Application to Commence Phase 2 Extramedullary AML & MDS Trial
Race Submits Human Ethics Application to Commence Phase 2 Extramedullary AML & MDS Trial
1 November 2021 – Race Oncology Limited (“Race”) is pleased to announce it has submitted the first human ethics application to the Hunter New England Human Research Ethics Committee (NSW, Australia) seeking approval to...
Race Initiates FTO Biomarker Research Collaboration with Chaim Sheba Israel
Race Initiates FTO Biomarker Research Collaboration with Chaim Sheba Israel
27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered into a research collaboration with Dr Dan Dominissini of the Chaim Sheba Medical Center, Israel to analyse clinical patient...
Race secures sixth US patent for Zantrene
Race secures sixth US patent for Zantrene
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF 19 October 2021 – Race Oncology (“Race”) is pleased to announce that it has...
Race secures fifth US patent for Zantrene
Race secures fifth US patent for Zantrene
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene® (bisantrene dihydrochloride). This...
Zantrene kills melanoma cancer cells that overproduce FTO
Zantrene kills melanoma cancer cells that overproduce FTO
Race Oncology Limited (“Race”) is pleased to share interim results from our collaborative preclinical melanoma research program with the University of Newcastle (ASX Announcement: 19 Mar 2021). Eminent melanoma researchers, Professor Xu Dong Zhang...
First Patient Dosed in Phase 1b/2 AML Trial at Chaim Sheba Medical Center Israel
First Patient Dosed in Phase 1b/2 AML Trial at Chaim Sheba Medical Center Israel
09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first patient has been dosed in the Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (ASX Announcement: 22 June 2021)....
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center to commence a Phase...
Race Executes Key Contract for Israel Phase 2 AML Trial
Race Executes Key Contract for Israel Phase 2 AML Trial
8 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed a contract with Trialog Clinical Trials Ltd, Israel, to support the coming combination Phase 2 Acute Myeloid Leukaemia trial....
Race Executes Contract to Commence Phase 2 Extramedullary AML Trial
Race Executes Contract to Commence Phase 2 Extramedullary AML Trial
2 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has appointed the Contract Research Organisation (CRO), Parexel International, to support an open label Phase 1/2 clinical trial in patients with...
